Reports Q4 revenue $108M, consensus $102.74M. “We delivered a strong finish to 2025, reflecting disciplined execution across the business and continued momentum in our core testing services, patient and digital solutions, and lab products,” said John W. Hanna, President and CEO of CareDx (CDNA). “As we enter 2026, we believe we are well positioned to build on this momentum and continue delivering meaningful value for transplant patients, clinicians, and shareholders.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDNA:
- CDNA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- CareDx: Solid Near-Term Beat but LCD Overhang and Reimbursement Uncertainty Justify Hold Rating
- CareDx reports preliminary Q4 revenue $108M, consensus $102.58M
- NeoGenomics CFO Jeff Sherman to retire, Abhishek Jain to succeed
- Craig-Hallum downgrades CareDx to Hold on less compelling risk-reward